

SIGN 122: Prevention and management of venous thromboembolism

Review report

Date	Update request	Decision	Status	Description
01/09/2014	Dabigatran, rivaroxaban, edoxaban and apixaban to be licensed for the treatment of VTE. Both initial therapy and ongoing therapy sections need to be updated to take account of this.	Update	Under review	
03/12/2013	Revision of evidence as relates to frail elderly patients with a particular focus on risk of bleeding. Revision of antenatal and postnatal guidance to consider further stratification of risk.	No update as constitutes new questions	n/a	n/a
04/07/2013	New evidence from the CLOTS 3 trial which showed that intermittent pneumatic compression reduced the risk of DVT and improved survival after stroke.	Update	Published October 2014	A minor update to section 6.2 in light of the CLOTS3 trial. The updated guideline recommends that IPC should be considered for use in patients immobilised after a stroke.
05/07/2012	New evidence and opinion on requirements for monitoring for HIT. The withdrawal of one of the two licensed drugs for this indication from the market with the introduction of a new licensed agent.	Update	Published October 2014	Section 15.2 on heparin induced thrombocytopenia updated to reflect changes in drug licensing and to ensure consistency with guidelines from the British Committee for Standards in Haematology.
11/10/2011	In the Wells Scoring system in Annex 5 it appears the category of 'previously documented DVT' has been left out. The range of scores given in Annex 5 is -2 to 9 when the highest score you can achieve using the categories given is 8. This suggests that previous DVT has been excluded as a risk factor.	Update	Published November 2011	Section 9.2 and Annex 5 covering diagnostic algorithms revised to clarify use of the Wells Scoring system.